NASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis $0.46 +0.02 (+4.58%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.44▼$0.4750-Day Range$0.40▼$1.0652-Week Range$0.34▼$1.82Volume1.90 million shsAverage Volume679,145 shsMarket Capitalization$17.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Unicycive Therapeutics alerts: Email Address Unicycive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside1,130.9% Upside$5.63 Price TargetShort InterestHealthy3.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.88) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector409th out of 936 stocksPharmaceutical Preparations Industry189th out of 436 stocks 3.6 Analyst's Opinion Consensus RatingUnicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnicycive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Unicycive Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.08% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unicycive Therapeutics has recently increased by 32.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for UNCY. Previous Next 3.1 News and Social Media Coverage News SentimentUnicycive Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Unicycive Therapeutics this week, compared to 1 article on an average week.Search Interest20 people have searched for UNCY on MarketBeat in the last 30 days. This is an increase of 567% compared to the previous 30 days.MarketBeat Follows3 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Unicycive Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Unicycive Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Unicycive Therapeutics Stock (NASDAQ:UNCY)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Read More UNCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UNCY Stock News HeadlinesJuly 20, 2024 | seekingalpha.comUNCY Unicycive Therapeutics, Inc.July 17, 2024 | globenewswire.comUnicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | americanbankingnews.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 22.5% in JuneJuly 11, 2024 | globenewswire.comUnicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceJuly 10, 2024 | globenewswire.comUnicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)July 1, 2024 | globenewswire.comUnicycive Therapeutics Joins Russell Microcap® IndexMay 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Unicycive Therapeutics Amid Promising Kidney Treatment AdvancesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 28, 2024 | globenewswire.comUnicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association CongressMay 23, 2024 | globenewswire.comUnicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceMay 15, 2024 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comUnicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical MeetingMay 14, 2024 | investorplace.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comUnicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | finance.yahoo.com3 Top Penny Stocks to Buy for Explosive Returns: April EditionApril 29, 2024 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper SandlerApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial PositioningSee More Headlines Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UNCY CUSIPN/A CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$5.63 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,130.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,540,000.00 Net MarginsN/A Pretax Margin-4,525.04% Return on EquityN/A Return on Assets-92.28% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$680,000.00 Price / Sales25.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-4.15Miscellaneous Outstanding Shares37,607,000Free Float28,544,000Market Cap$17.19 million OptionableNot Optionable Beta2.39 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Shalabh K. Gupta M.D. (Age 51)MPA, Founder, Chairman, CEO & President Comp: $1.46MDr. Pramod Gupta Ph.D. (Age 64)Executive Vice President of Pharmaceutical & Business Operations Comp: $779.18kMr. Douglas Jermasek M.B.A. (Age 62)Executive Vice President of Corporate Strategy Comp: $430.81kMr. John W. Townsend CPA (Age 62)Chief Financial Officer Comp: $197.86kKey CompetitorsProPhase LabsNASDAQ:PRPHTurnstone BiologicsNASDAQ:TSBXCelularityNASDAQ:CELUImmix BiopharmaNASDAQ:IMMXDURECTNASDAQ:DRRXView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Sold 308,446 shares on 7/12/2024Ownership: 4.178%Virtu Financial LLCBought 26,082 shares on 5/20/2024Ownership: 0.069%BVF Inc. ILBought 1,493,462 shares on 5/16/2024Ownership: 9.603%View All Institutional Transactions UNCY Stock Analysis - Frequently Asked Questions How have UNCY shares performed this year? Unicycive Therapeutics' stock was trading at $0.8677 at the start of the year. Since then, UNCY shares have decreased by 47.3% and is now trading at $0.4570. View the best growth stocks for 2024 here. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) announced its quarterly earnings results on Monday, May, 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.09. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. Who are Unicycive Therapeutics' major shareholders? Unicycive Therapeutics' top institutional shareholders include Rosalind Advisors Inc. (4.18%). View institutional ownership trends. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UNCY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
